Kornimate/medical-research-clean huggingface dataset:
automate detection of sleep apnea by apneascantm

Conditions: Sleep Apnea; Arrhythmias

Summary: the purpose of the study is to compare, three months after implantable cardioverter-defibrillator (icd) or cardiac resynchronization therapy-defibrillator (crt-d), the apnea-hypopnea index (ahi) obtained from conventional in-lab npsg/npg (ahipsg) with similar indices obtained from autoscoring algorithms of the apneascan™, an implantable impedance-based respiration sensor (ahias).

this is a prospective, multi center, phase-iv with blinded analysis and central reading of polysomnography trial. the study is performed in patients with a standard crt-d or implantable cardioverter defibrillator (icd) devices indication. a total of 160 subjects will be recruited in france. the study duration is 03 months for each subject.

Eligibility criteria:
inclusion criteria: * male and female aged \> 18 years old * current icd or crt-d device-based guidelines indication (for primo-implantation) * patients with optimal recommended medical therapy * patient willing and able of undergoing the device implant procedure * patient willing and able of undergoing the latitude® nxt patient management system procedure * patient willing and able to complete the requirements of the study including the signature of the informed consent after full explanation of the study by the investigator prior to participation. exclusion criteria: * obstructive lung disease as defined by a fev1/fvc less than 70% * obesity hypoventilation syndrome * treated sleep disorders breathing * cardiac surgery scheduled or strong likelihood of cardiac surgery 4 months after enrollment * life expectancy less than 1 year * inability to complete overnight psg as defined by the protocol * patient who are or suspected to be pregnant and or plan to become pregnant * patient protected by the law, under guardianship or curators * concomitant participation in an interventional biomedical research trial

Keywords: sleep apnea, arrhythmias, heart failure, icd, crt-d, apneascan
neoadjuvant radiochemotherapy combined with ql1706 for low rectal cancer

Conditions: Rectal Cancer

Summary: this study investigates the efficacy of neoadjuvant radiotherapy combined with ql1706 in mss-type low-grade rectal cancer. this study is a prospective multicohort study, with cohort 1 intended to include patients with low grade early rectal cancer (ct1-3n0m0) and cohort 2 intended to include patients with low grade locally advanced rectal cancer (ct4n0m0 or ctanyn+m0). each cohort included 30 subjects receiving neoadjuvant radiotherapy combined with ql1706 treatment.


Eligibility criteria:
inclusion criteria: 1. patients willing to receive neoadjuvant therapy. 2. aged 18-75 years, regardless of gender. 3. diagnosed with low-lying rectal adenocarcinoma (tumor located ≤7 cm from the anal verge) via colonoscopy, endorectal ultrasound, and pelvic high-resolution mri, without distant metastasis. 4. histopathologically confirmed rectal adenocarcinoma. 5. good patient compliance, able to attend follow-up visits as required. 6. ecog performance status score of 0-1. 7. laboratory tests meeting the following criteria: i. wbc ≥3.5×10\^9/l, anc ≥1.8×10\^9/l, platelets ≥100×10\^9/l, hemoglobin ≥100 g/l. ii. inr ≤1.5, aptt ≤1.5×uln, or ptt ≤1.5×uln. iii. total bilirubin ≤1.25×uln; alt/ast ≤5×uln. iv. 24-hour creatinine clearance ≥50 ml/min or serum creatinine ≤1.5×uln. 8. voluntary signed informed consent. exclusion criteria: 1. history of malignant colorectal tumors. 2. patients requiring emergency surgery (e.g., intestinal obstruction, perforation, or hemorrhage). 3. known allergy to capecitabine, oxaliplatin, pd-l1 inhibitors, ctla-4 inhibitors, or related drugs. 4. histopathology indicating poorly differentiated adenocarcinoma or signet ring cell carcinoma. 5. unstable systemic diseases, including but not limited to: severe infection, uncontrolled diabetes, refractory hypertension, unstable angina, cerebrovascular accident, myocardial infarction, congestive heart failure, life-threatening arrhythmias, or severe hepatic/renal/metabolic disorders. 6. conditions (e.g., psychiatric disorders, substance abuse) that may increase treatment risk, compromise compliance, or confound study results. 7. participation in another interventional clinical trial or use of investigational drugs within 30 days prior to screening. 8. pregnancy, lactation, or refusal to use effective contraception during the study. 9. other conditions deemed unsuitable by the investigator.
effect of increasing time spent outdoors on myopia prevention in school-aged children in northeast china

Conditions: Myopia

Summary: the purpose of this study is to develop a school-based intervention aimed at prevent the onset and development of myopia among school aged children by increasing time spent outdoors in northeast china.

the purpose of this study is to develop a school-based intervention aimed at prevent the onset and development of myopia among school aged children by increasing time spent outdoors among elementary and secondary school students in northeast china. it is expected that the results will provide evidences for policy-makers and school healthcare providers for their school children myopia prevention.

Eligibility criteria:
inclusion criteria: * grade of 1 to 5 in elementary schools and grade of 7 to 8 in secondary schools. exclusion criteria: * visual defect or other eye diseases; wearing orthokeratology; refractive surgery history.

Keywords: vision, ocular physical activity schoolchildren intervention studies
treatment of zollinger-ellison syndrome with prevacid

Conditions: Zollinger-Ellison Syndrome; Multiple Endocrine Neoplasia

Summary: the purpose of this study is to study the safety and efficacy of high dose prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.

the aim of this protocol is to study the medical management of acid hypersecretory states including zollinger-ellison using prevacid. the immediate objective is to heal peptic ulcers and eliminate symptoms and in the long term to prevent relapse of symptoms, lesions and complications. other objectives include observation of the efficacy in controlling gastric acid production and of the safety of high dose, long-term use of prevacid.

Eligibility criteria:
inclusion criteria: * diagnosed with zollinger-ellison syndrome exclusion criteria: * pregnant or lactating females
comparison of the natural frequencies technology sleep patches to sham patches during sleep in the home environment

Conditions: Sleep Disturbance

Summary: prospective, randomized crossover study to compare the nft sleep patches to sham device to assess sleep via home sleep testing device in the home environment


Eligibility criteria:
inclusion criteria: * capacity to provide informed consent * bmi \<30 * between 30 and 65 years old * in overall good health as determined by history and physical assessment subjects pre-screened to ensure they are drug free * work a typical day job/work week. * not traveled \> 3 time zones in the last month * typical bedtime between 9-12 pm * estimated on average 6 hours per night * negative urine drug screen * have self-reported unrefreshing sleep for the past month * agree to limit alcohol use to no more than two drinks a night during the testing period and four hours prior to bedtime * agree to limit caffeine consumption to four hours prior to bedtime * ≤ 2 on the depression scale * ≤ 3 on the anxiety scale exclusion criteria: * pregnant or nursing a child * self-induced short sleep habits (\<6 hours per night) * unstable medical conditions as determined by the clinician * current sleep disorder (sleep apnea ahi/rei\<5, restless legs, periodic limb movements, narcolepsy) * self-reported sleep latency of \>30 minutes or early (3-4 am) awakenings on a regular basis * contact dermatitis to adhesives * excluded medications: over the counter sleep aids, prescribed sleep aids, central nervous system stimulants, antidepressants, sedating antihistamines, over the counter decongestants and opioids
predictive significance of teg on end in patients with acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the purpose of this study is to evaluate whether thromboelastography (teg) parameters on admission might be predictive for early neurological deterioration in acute ischemic stroke patients, specifically for the dwi lesion evolution within the first week after stroke onset.

early neurological deterioration (end ) is a major concern in stroke care, consistently associated with adverse clinical outcomes.end is a heterogeneous complex of pathophysiological and clinical entities. despite some straight forward causes, dwi lesion growth is reportedly a primary underlying mechanism. early recognition of end risk would allow for timely identification and proper intervention, improving stroke health care. thromboelastography (teg) measures the coagulation process from initial clotting cascade to clot strength, providing an integrated picture of two separate but simultaneously occuring components of coagulation, thrombosis and lysis. it has been reported to be associated with short and long-term outcome in patients with trauma, coronary artery diseases , pulmonary embolism and, most recently, stroke prevention.the purposes of this study is to evaluate how effective teg is on predicting end, by producing a range of teg values correlated with clinical and radiological assessment.

Eligibility criteria:
inclusion criteria: * acute ischemic stroke within 24 hours after symptom onset * first ever stroke * give informed consent exclusion criteria: * receiving thrombolysis * cardiogenic embolism * contradiction to serial mri studies * taking hemostatic agents (warfarin, oral anticoagulants and etc. )
tonicity of perioperative maintenance solutions

Conditions: Thoracic Diseases; Water-Electrolyte Imbalance; Fluid Overload; Fluid Retention; Sodium Disorder; Potassium Disorders; Chloride Disorder

Summary: prospective randomized double blind phase iv trial studying the efficacy and safety of the tonicity of two different perioperative maintenance solutions: an isotonic solution containing nacl 0.9 in glucose 5% with an added 40 mmol/l of potassium or a commercially available premixed solution (glucion 5%) containing a.o. 54 mmol/l of sodium and 26 mmol/l of potassium. both solutions are administered at 27 ml/kg of ideal body weight, as recommended by current guidelines (nice 174) and both solutions are widely used in daily clinical practice. the primary hypothesis is that isotonic maintenance solutions lead to more fluid retention than hypotonic fluids. metabolism of both solutions is assessed by sequential analysis of urine and serum and clinical parameters.


Eligibility criteria:
inclusion criteria: * adult (at least 18 y.o.) * undergoing elective lung resection (wedge resection, segmental resection, (bi)lobectomy, but not pneumonectomy) via thoracotomy or video- or robot assisted (vats, rats) * normal renal function (egfr \>60 ml/min/1.73m² (ckd-epi)) exclusion criteria: * under chronic treatment with diuretics or desmopressin * heart failure (nyha iii-iv) * liver failure * brittle diabetes mellitus * neurological contra-indication for hypotonic fluids * siadh or hyponatremia \ 150 mmol/l at preoperative assessment * hyperkalemia \> 5 mmol/l at preoperative assessment * under treatment with artificial nutrition (enteral or parenteral) * pregnancy additional pre-defined exclusion after initial inclusion * massive perioperative transfusion or intraoperative resuscitation of +2.5l of crystalloids/colloids * absence of admission to icu

Keywords: maintenance fluid therapy
effects of atrial rate-adaptive pacing on exercise capacity in patients with chronic heart failure complicated by chronotropic incompetence

Conditions: Heart Failure; Exercise Tolerance

Summary: chronotropic incompetence consists of an insufficient increase in heart rate during effort, and its presence is recognized as a common feature in patients with heart failure due to left ventricular systolic dysfunction, apparently suggesting a worse prognosis. little is known about the possible benefits of its reversal in such patients. the investigators working hypothesis is that the modulation of chronotropic response, as obtained by means of atrial rate-adaptive pacing may improve functional capacity in persons with chronic heart failure and chronotropic incompetence. to explore this hypothesis,the investigators will enroll 20 patients with nyha ii/iii heart failure, low left ventricular ejection fraction (\<40%) and chronotropic incompetence (maximal heart rate \<80% of predicted value in a symptom-limited incremental test), who already underwent implantation of dual-chamber implantable defibrillator for prevention of sudden cardiac death. the study will have a randomized, double-blind, cross-over design. the procedures, to be carried out at one month from each reprogramming (vvi backup pacing vs. aai-r "active" pacing), will comprise: blood sampling for nt-probnp, incremental symptom-limited cardiopulmonary exercise testing (cpx), constant-workload cardiopulmonary test (50% of max wr), quality-of-life questionnaire, 24-hour ecg monitoring. the primary end-point will be peak oxygen consumption on cpx. secondary end-points will include acute response to reprogramming, and data derived from constant-wr tests, holter monitoring and qol.


Eligibility criteria:
inclusion criteria: * nyha ii/iii chronic heart failure on optimal medical therapy * sinus rhythm * left ventricular ejection fraction less than 40 % * chronotropic incompetence on maximal exercise testing (maximum heart rate \< 80% of predicted value) * age 18-75 * carrier of dual chamber icd device * informed consent exclusion criteria: * unable to perform cardiopulmonary exercise testing (for any reason) * absolute contraindication to maximal exercise testing * moderate to severe anemia (hb\<10 g/dl) * diagnosis of sick sinus syndrome or high-degree atrioventricular block * recent hospitalization for acute decompensated heart failure (\<1 month) * recent acute coronary syndrome (\<3 months) * active neoplastic disease * active myocarditis / endocarditis * acute decompensated heart failure during study

Keywords: cardiac pacing heart failure oxygen consumption ventricular dysfunction left, exercise tolerance chronotropic incompetence pacemaker programming
dopamine treatment in children with cerebral palsy with dystonia- a double blind controlled study

Conditions: Dystonic Cerebral Palsy

Summary: background: cerebral palsy (cp) is the main cause of childhood immobility and is defined as a non progressive injury to the developing central nervous system in children younger than 3 years, resulting in neurological and musculoskeletal abnormalities. the main pathophysiological causes are encephalopathy of prematurity (periventricular leukomalacia) hypoxic ischemic encephalopathy. infections, infracts and migration defects are other less common causes of cp. the brain injury leads to functional motor impairment impacting on daily activities commonly manifests as a movement disorder: pyramidal, leading to spasticity and extra-pyramidal leading to dystonia and chorea. in most cases extensive brain injury causes a mixed movement disorder. dystonia is defined as involuntary muscle contractions causing twisting and abnormal postures. while the neurological underpinnings of cp remain unknown, a link between low dopamine and increased acetylcholine release has recently been reported in dystonia. dopamine is considered the first line of treatment in children with dystonia and cp followed by anticholiergic treatment with trihexphenidyl. the recommendation of dopaminergic treatment is based on need to rule out dopamine-responsive-dystonia, a rare genetic disorder, and on single case study reporting improvement in cp. a double blind study support or refute the use of dopamine treatment for dystonic cp was never reported. working hypothesis and aims: in children with cp due to a clear underlying pathology, dopamine treatment will not improve daily function. methods: the investigators will perform a double blinded randomized controlled crossover study. 50 children ages 4-18 years with a clear pathophysiological cause for cp will be enrolled. each child will receive dopamine and placebo treatment for 2 weeks with a 2 week washout interval. participants will be randomized into 2 groups; one will receive placebo followed by dopamine and the other vice versa. the primary outcome measure, goal-attainment-scale, and secondary outcome functional measures (such as box and blocks, 9 hole pegs, pronation/ supination, finger sequencing) will be assessed at the beginning and end of each treatment as well as parent questionnaires regarding satisfaction and side effects. expected results: no functional improvement with dopamine treatment compared to placebo. importance: supplying sufficient data to support or refute the use of dopamine treatment for dystonic cp. probable implications to medicine: this may lead to a change in medical treatment guidelines for children with cp.


Eligibility criteria:
inclusion criteria: * clear pathophysiological cause for cp * disabling dystonia in upper limbs exclusion criteria: * significant contractures * psychiatric disorder
comparison of positive end expiratory pressure titration methods in ards patients

Conditions: Acute Respiratory Distress Syndrome

Summary: this study aims at assessing the short-term physiological effects of 2 positive end expiratory pressure titration strategies in patients with ards.


Eligibility criteria:
inclusion criteria: * age\> 18 years * moderate or severe ards * consent to participation obtained from a relative exclusion criteria: * protect adult * pregnant or breastfeeding woman * no-affiliation to the social security scheme * contra-indication to the placement of an esophageal pressure measuring catheter * pneumothorax * hemodynamic and / or respiratory instability * extra-corporeal membrane oxygenation

Keywords: ards esophageal pressure mechanical ventilation
influence of anthropometric data, shoulder complex muscle strength, and abdominal-lumbar endurance in closed kinetic chain upper extremity stability test

Conditions: Shoulder Pain

Summary: a previous study of the closed kinetic chain upper extremity stability test (epoltest) in a population aged 18 to 25 years isolated 3 main factors influencing the ckcuest score: upper extremity span, weight, and sex of the individual. a predictive equation for the ckcuest score was thus established and to date has a capacity to determine the real score of approximately 51%. the results of this first study show that a certain number of variables have not been studied. the purpose of this study, epoltest 2, is to take into account the variables already studied on a larger population (18-50 years old) and to add an assessment of shoulder muscle strength and abdominolumbar endurance.


Eligibility criteria:
inclusion criteria: * aged to 18 to 50 years * capacity to consent * who has signed the consent exclusion criteria: * fracture history or upper limb luxation \< 1 year * pain or discomfort that prevents the test from being performed * history of abdominal surgery or hernia \< 1 year * pregnant or nursing * refuse to participate * guardianship or protection of vulnerable adult

Keywords: ckcuest physical activity rehabilitation
coenzyme q10 and dentoalveolar cyst

Conditions: Cyst, Jaw

Summary: 10 patients in each group will undergo cyst removal under local anesthesia. after cyst removal, the cystic cavity will be filled with placebo gel in the control group or coenzyme gel in the coenzyme group. bone density and volume will be assessed by cone beam ct immediately postoperative and 6months later for all patients


Eligibility criteria:
inclusion criteria: * adult patients with critical-size jaw cysts * medically stable * no cystic lesion recurrence exclusion criteria: * cystic lesion recurrence * medical problem
examining the effects of mitochondrial oxidative stress in dcm

Conditions: Dilated Cardiomyopathy

Summary: double blind, randomised, placebo-controlled trial of mitoq (mitoquinol mesylate) in 106 patients with dilated cardiomyopathy, examining the effect of reducing mitochondrial oxidative stress on myocardial energetics and myocardial function using 31-phosphorus magnetic resonance spectroscopy and cardiovascular magnetic resonance.


Eligibility criteria:
inclusion criteria 1. idiopathic or familial dcm 2. lvef ≤45% on 2 imaging studies of any modality ≥3 months apart (may include cmr scan at baseline visit) 3. on guideline therapy for ≥3 months as determined by usual clinicians 4. sinus rhythm on 12-lead electrocardiogram 5. plasma nt-pro-bnp \>250ng/l for those \>65 years and \>100ng/l for those aged ≤65 years within the last 6 months (may include sample at baseline visit) exclusion criteria 1. current persistent atrial fibrillation 2. contraindication to cmr 3. estimated glomerular filtration rate (egfr) \<30mls/min 4. current or planned pregnancy or current breast-feeding 5. clear environmental trigger such as excess alcohol intake, cardiotoxic chemotherapy or peripartum presentation 6. fibrosis burden \>25% on cmr 7. current cancer (other than non-melanoma skin cancers) 8. current use of coq10 9. current participation in another randomised controlled trial

Keywords: energetics mitochondria oxidative stress
determination of the rankl/osteoprotegerin ratio in patients with systemic lupus erythematosus. role in osteoporosis and cardiovascular calcification

Conditions: Osteoporosis; Lupus Erythematosus, Systemic

Summary: patients with systemic lupus erythematosus (sle) are known to present an increased risk of osteoporosis and cardiovascular calcification. it has also been suggested that bone remodelling and cardiovascular calcification are regulated by the same mechanisms, but inversely in terms of calcium deposition, as osteoporosis is often associated with cardiovascular calcification. inflammatory and immune factors have been implicated in these two processes. the role of the rankl/opg system in osteoclast differentiation has been elucidated over the last ten years. rankl induces differentiation of monocytes-macrophages into osteoclasts, while, inversely, opg exerts an inhibitory role by inactivating rankl. differentiation of smooth muscle cells into osteoblasts in the vessel wall induces calcification, and this phenomenon is counterbalanced by differentiation of monocytes into osteoclasts. although the role of the rankl/opg ratio in the pathogenesis of osteoporosis has now been clearly established, its role in vascular calcification is only hypothetical at the present time. this study will focus on patients with sle diagnosed and followed in the amiens university hospital internal medicine and nephrology departments


Eligibility criteria:
inclusion criteria: * women over 18 years old * suffering from systemic lupus erythematosus. exclusion criteria: underlying diseases that can lead to bone and cardiovascular metabolic disturbances : * malignancies such as cancer metastasized * autoimmune disease other than led or of overlap syndrome ( rhupus , mctd ) * infection by hiv, hepatitis b and c * hepatic cirrhosis * chronic renal failure * parathyroid disorders

Keywords: cardiovascular calcification rank: receptor activator of nuclear factor kappa b rankl: receptor activator of nuclear factor kappa b ligand opg: osteoprotegerin sle: systemic lupus erythematosus